Translational science and biomarker strategy
Each biomarker page labels its evidence by type, from FDA companion diagnostic to curated actionability to association, and links it to the drugs and trials that use it.
Individual plan, $249/seat/mo. Card required.
A gene shows up in an association database, a handful of trial eligibility criteria and one companion diagnostic label, and each source uses its own identifier. Deciding whether the biomarker is actionable means reading all of them and keeping the evidence types apart. A strategy slide that blurs association and validation gets corrected by the first clinician who reads it.
Pages marked free open without an account. The rest open in the product, starting with a 14-day trial.
Every biomarker page sorts its evidence into FDA companion diagnostic assertions, curated cancer actionability, trial mentions and target-disease associations, so an association is not read as validation. Open the BRAF page to see one gene's evidence split across those types. The BRAF page lists 19 FDA companion diagnostic assertions today.
Free to read Biomarkers Open the BRAF page
The biomarker hub groups every public biomarker by evidence tier and states in a plain sentence what each tier means. A target-disease association is never presented as a validated biomarker with an assay behind it. 322 biomarker pages are free to read today.
Free to read Biomarkers
A condition page ties a disease to its registered trials by phase and by start year and to a Top publications table of papers whose own MeSH tags point at it, each linking to PubMed. Alzheimer Disease is a worked example. 3,859 registered trials study Alzheimer Disease or one of its sub-conditions.
Free to read Conditions Open the Alzheimer Disease page
A target page lists the drugs acting on it and the companies developing against it, with its programs by phase and its discontinued programs. It also shows predicted and experimental structures.
In the product: Targets
A drug page gathers one molecule's brands, trial variants and development programs, so compounds filed under different names are read as one. Use it to follow a mechanism across every program built on the same molecule.
In the product: Chemical Entities
The Program explorer lists development programs as drug and indication pairs and filters them by the highest phase reached, from any phase to Phase 4. Read the phase to see how far a hypothesis got.
In the product: Programs
Yearly trial and publication counts on a biomarker page reflect the studies and papers the biomarker matching recognized, which is a subset of the literature. Each page lists the evidence types that were looked for and found empty.
Every answer above marked "In the product" opens with the Individual plan.
Individual plan, $249/seat/mo, card required.
